Soleno Therapeutics (SLNO) has been initiated with Buy at Goldman Sachs citing strong fundamentals and blockbuster potential for its lead asset, Vykat XR, in treating Prader-Willi syndrome. After ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best healthcare stocks with the highest upside. Goldman Sachs initiated ...

Goldman Sachs initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $125 price target The firm sees the company’s Vykat XR ...

The defence sector has been hot in 2025 and shares in these three companies have surged by 65% or more in the past few months ...

Samsung is expected to officially launch the Galaxy XR headset, a major rival to the Vision Pro, in late October. Pre-registration for the device, built in partnership with Google and Qualcomm on the ...

TL;DR: Samsung will launch its advanced Galaxy XR headset on October 22, featuring Qualcomm's Snapdragon XR2 Plus Gen 2 chipset, 16GB VRAM, and a 3800 PPI micro-OLED display surpassing Apple's Vision ...

Samsung's first Android XR headset, codenamed Project Moohan, was rumored to launch on September 29, but it has reportedly been delayed to October 21. While we are still awaiting official confirmation ...

Effexor XR (venlafaxine) is a prescription drug used to treat depression, panic disorder, and certain types of anxiety. It comes as an extended-release oral capsule. (Extended-release capsules slowly ...

Samsung is finally launching its long-anticipated Android XR headset, officially dubbed Galaxy XR. The headset clearly aims to deliver a Vision Pro experience (plus some of its own unique abilities) ...

Soleno Therapeutics (SLNO) shares have been active lately, catching investor attention after a short-seller report questioned the safety and outlook of its VYKAT XR drug. This was quickly followed by ...

ROCHESTER — It’s 9 a.m. Monday at 125 Live and the place is hopping. In one class, people are gracefully gliding to Tai Chi rhythms. In another, arms are swinging, legs are kicking to an aerobics ...